	US 7,612,212 B2
	Substituted hydantoins
Shaoqing Chen, Bridgewater, N.J. (US); Nicholas J. S. Huby, Scotch Plains, N.J. (US); Norman Kong, West Caldwell, N.J. (US); Steven Gregory Mischke, Florham Park, N.J. (US); John Anthony Moliterni, Bloomfield, N.J. (US); Hong Wang, Nutley, N.J. (US); and Zhuming Zhang, Hillsborough, N.J. (US)
Assigned to Hoffmann-La Roche Inc., Nutley, N.J. (US)
Filed on Jan. 25, 2007, as Appl. No. 11/657,800.
Claims priority of provisional application 60/775658, filed on Feb. 22, 2006.
Claims priority of provisional application 60/861105, filed on Nov. 27, 2006.
Prior Publication US 2007/0197617 A1, Aug. 23, 2007
Int. Cl. C07D 233/02 (2006.01); A61K 31/4166 (2006.01)

U.S. Cl. 548—317.1 [514/389]

16 Claims

1. A compound of formula I:

wherein:

R1 is selected from the group consisting of bromo, iodo, ethynyl, cycloalkyl, alkoxy, azetidinyl, acetyl, heterocycyl, cyano, straight-chained alkyl and branched-chain alkyl;

R2 is selected from the group consisting of hydrogen, chloro, fluoro, and alkyl;

R3 is selected from the group consisting of hydrogen and fluoro;

R4 is selected from the group consisting of optionally substituted aryl, alkyl, and cycloalkyl;

R5 is selected from the group consisting of hydrogen and

wherein R6 is selected from the group consisting of hydroxyl, alkoxy, cycloalkyl, trihaloalkyl, alkyl, optionally substituted aryl, and optionally substituted heteroaryl;

R7 and R8 are independently selected from the group consisting of hydrogen, alkyl, and trihaloalkyl; or

R6 and R7 can together form a cycloalkyl group and R8 is hydrogen;

and pharmaceutically acceptable salts or esters thereof.